The diabetes drug rosiglitazone has been under intense scrutiny since a 2007 study linked the drug's use with increased risk of heart attack and death from heart disease. Now, in a post-trial analysis of results from an international clinical trial of diabetes patients with cardiovascular disease, researchers at several major centers across the country report no increased rate of heart attack or death in patients taking the drug.